1. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective. Issue 1 (June 2015) Authors: Charokopou, M.; McEwan, P.; Lister, S.; Callan, L.; Bergenheim, K.; Tolley, K.; Postema, R.; Townsend, R.; Roudaut, M. Journal: BMC health services research Issue: Volume 15:Issue 1(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus. Issue 7 (30th April 2015) Authors: Charokopou, M.; McEwan, P.; Lister, S.; Callan, L.; Bergenheim, K.; Tolley, K.; Postema, R.; Townsend, R.; Roudaut, M. Journal: Diabetic medicine Issue: Volume 32:Issue 7(2015:Jul.) Page Start: 890 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗